Sign in
Back
IS THERE A MORTALITY BENEFIT WITH RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IN AFRICAN AMERICANS (AA) WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)?
Journal article   Open access  Peer reviewed

IS THERE A MORTALITY BENEFIT WITH RENIN-ANGIOTENSIN SYSTEM (RAS) INHIBITION IN AFRICAN AMERICANS (AA) WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)?

Ravinder Valadri, Emir Veledar, radhika gadesam, Saumeth Cardona, Jo Ann Cross, Gregory Strayhorn, Heather L. Bloom, Adefisayo Oduwole, David B. De Lurgio, Javed Butler, …
Journal of the American College of Cardiology, Vol.59(13)
2012
DOI: https://doi.org/10.1016/s0735-1097(12)60961-9

Abstract

RAS inhibitors (RASIs/ACE inhibitors & ARBs) have reduced mortality in SHF (EF 45p) in randomized controlled trials. Since, AAs are underrepresented in these trials, whether these results are applicable to AAs with HFPEF is uncertain All cause mortality was
url
https://lens.org/153-906-246-142-746View
url
https://www.sciencedirect.com/science/article/pii/S0735109712609619View
url
https://www.jacc.org/doi/10.1016/S0735-1097%2812%2960961-9View
url
https://core.ac.uk/download/pdf/82079797.pdfView
url
https://doi.org/10.1016/s0735-1097(12)60961-9View
Published (Version of record) Open

Metrics

4 Record Views

Details